Senhwa Biosciences, Inc. (TPEX: 6492)
Taiwan
· Delayed Price · Currency is TWD 46.90
-1.30 (-2.70%)
Sep 10, 2024, 1:30 PM CST
Senhwa Biosciences Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1 | 1 | 1 | 0.55 | 0.62 | 0.3 | Upgrade
|
| Revenue Growth (YoY) | 0% | 0% | 81.82% | -10.86% | 105.67% | -59.07% | Upgrade
|
| Cost of Revenue | 0.45 | 0.45 | 0.5 | 0.23 | 0.27 | 0.26 | Upgrade
|
| Gross Profit | 0.55 | 0.55 | 0.51 | 0.32 | 0.35 | 0.04 | Upgrade
|
| Selling, General & Admin | 61.99 | 54.79 | 43.77 | 71.17 | 83.24 | 56.8 | Upgrade
|
| Research & Development | 244.26 | 256.87 | 312.85 | 275.47 | 276.37 | 337.03 | Upgrade
|
| Operating Expenses | 306.25 | 311.66 | 356.62 | 346.64 | 359.61 | 393.84 | Upgrade
|
| Operating Income | -305.7 | -311.11 | -356.12 | -346.32 | -359.26 | -393.8 | Upgrade
|
| Interest Expense | -0.58 | -0.54 | -0.54 | -0.53 | -0.26 | -0.34 | Upgrade
|
| Interest & Investment Income | 6.69 | 7.64 | 7.32 | 4.61 | 4.02 | 6.21 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.02 | 0.49 | -1 | 1.24 | 0.43 | -2.41 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.79 | - | 0.01 | 0.92 | 0.2 | 0.64 | Upgrade
|
| EBT Excluding Unusual Items | -298.82 | -303.52 | -350.34 | -340.06 | -354.87 | -389.7 | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.54 | 8.04 | 2.08 | 1.52 | 0.49 | - | Upgrade
|
| Other Unusual Items | - | 0.43 | - | 10.2 | - | - | Upgrade
|
| Pretax Income | -290.28 | -295.05 | -348.26 | -328.35 | -354.38 | -389.7 | Upgrade
|
| Income Tax Expense | 1.26 | 1.26 | 1.37 | 0.91 | 0.5 | 1.72 | Upgrade
|
| Net Income | -291.54 | -296.31 | -349.63 | -329.26 | -354.88 | -391.43 | Upgrade
|
| Net Income to Common | -291.54 | -296.31 | -349.63 | -329.26 | -354.88 | -391.43 | Upgrade
|
| Shares Outstanding (Basic) | 89 | 89 | 89 | 90 | 79 | 74 | Upgrade
|
| Shares Outstanding (Diluted) | 89 | 89 | 89 | 90 | 79 | 74 | Upgrade
|
| Shares Change (YoY) | - | -0.00% | -0.50% | 13.49% | 6.06% | 0.07% | Upgrade
|
| EPS (Basic) | -3.27 | -3.32 | -3.92 | -3.67 | -4.49 | -5.26 | Upgrade
|
| EPS (Diluted) | -3.27 | -3.32 | -3.92 | -3.67 | -4.49 | -5.26 | Upgrade
|
| Free Cash Flow | -282.06 | -290.96 | -400.34 | -300.29 | -273.07 | -384.83 | Upgrade
|
| Free Cash Flow Per Share | -3.16 | -3.26 | -4.49 | -3.35 | -3.46 | -5.17 | Upgrade
|
| Gross Margin | 54.80% | 55.20% | 50.50% | 58.73% | 56.89% | 12.67% | Upgrade
|
| Operating Margin | -30570.10% | -31111.10% | -35611.50% | -62966.55% | -58226.74% | -131266.67% | Upgrade
|
| Profit Margin | -29153.80% | -29630.60% | -34963.20% | -59864.91% | -57516.69% | -130475.33% | Upgrade
|
| Free Cash Flow Margin | -28205.70% | -29095.90% | -40034.00% | -54597.64% | -44257.86% | -128275.67% | Upgrade
|
| EBITDA | -303.65 | -309.53 | -355.81 | -345.86 | -357.94 | -391.54 | Upgrade
|
| D&A For EBITDA | 2.06 | 1.58 | 0.31 | 0.46 | 1.32 | 2.27 | Upgrade
|
| EBIT | -305.7 | -311.11 | -356.12 | -346.32 | -359.26 | -393.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.